Loading provider…
Loading provider…
Vascular Neurology Physician in Los Angeles, CA
NPI: 1366679508Primary Practice Location
RONALD REAGAN UCLA MEDICAL CENTER
757 Westwood Plz, Los Angeles, CA
Primary Employer
UCLA Neurology Group Practice
uclahealth.org
HQ Phone
Get MD May's Phone Numberphone_androidMobile
Get MD May's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2010 - 2026
CA State Medical License

American Board of Psychiatry and Neurology
Neurology

National Board of Physicians and Surgeons
Neurology
UCLA David Geffen School of Medicine/UCLA Medical Center
Residency • Neurology
2010 - 2013
University of Arizona College of Medicine-Phoenix
Internship • Internal Medicine
2009 - 2010
College of Medicine - Tucson
medicine.arizona.edu
Medical School
Until 2009
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99223Initial hospital inpatient care, typically 70 minutes per day | 54 | 62 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 27 | 61 |
| 3 | 99239Hospital discharge day management, more than 30 minutes | 18 | 18 |
| 4 | 99152Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 15 minutes | 13 | 13 |
Prospective, Multicenter, Controlled Trial of Mobile Stroke Units.
Authors: Joseph Kass, Saad Mir, David Persse, Janice Miller, Andrei Alexandrov, Joey English, James Grotta, Nobl Barazangi, Vivek Misra, Elizabeth Noser, Jason Mackey
Journal: N Engl J Med
Imaging of cerebral ischemia: from acute stroke to chronic disorders.
Reperfusion Therapy Frequency and Outcomes in Mild Ischemic Stroke in the United States.
Authors: Viktor Szeder, Satoshi Tateshima, Hamidreza Saber, David Liebeskind
Publication Date: 2020-10-21
Lead Sponsor: Joseph Broderick, MD
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS), Novo Nordisk A/S
Intervention / Treatment: BIOLOGICAL: Placebo, BIOLOGICAL: Recombinant Activated Factor VII (rFVIIa)